Hexarelin

Also known as: Examorelin

Evidence Tier B-Chigh riskadvancednot approved

GHRP-class secretagogue with stronger GH stimulation and studied sleep-endocrine effects.

WADA S2

This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.

GH Axis

This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.

Overview

Hexarelin (examorelin) is a GHRP-class secretagogue often showing stronger GH stimulation than some peers. Human volunteer studies used repetitive administration (e.g., 4x50 Âµg across night hours) to evaluate GH/ACTH/cortisol/prolactin and sleep EEG outcomes. Endocrine spillover effects have been studied.

Research Details

Mechanism of Action

GH secretagogue; often stronger GH stimulation vs some peers; spillover endocrine effects studied.

Study Dose Range

Human: repetitive 4x50 Âµg across night hours in sleep-endocrine studies.

Administration Routes

subcutaneous, intravenous

Onset / Timeline

Acute endocrine effects; sleep effects studied overnight.

Expected Effects

GH-axis modulation; sleep architecture research interest.

Adverse Effects

Endocrine spillover (ACTH, cortisol, prolactin).

Contraindications

No formal label.

Interaction Notes

Unknown; caution with other GH-axis compounds.

Related Goals

Muscle Growth & StrengthSleep & RelaxationGH Axis Optimization

Known Interactions

caution with MK-677

Hexarelin plus MK-677 creates multiple GHS-pathway inputs with limited combination safety support.

Available From

No vendors currently listed for this peptide.

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Sermorelin

GHRH(1-29) analogue that stimulates pulsatile GH secretion, historically used in clinical settings.

Tier B

Tesamorelin

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Tier A

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.